Doxazosin
- Generic Name
- Doxazosin
- Brand Names
- Cardura
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N5O5
- CAS Number
- 74191-85-8
- Unique Ingredient Identifier
- NW1291F1W8
- Background
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
- Indication
Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hypertension and the treatment of ureteric calculi.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus
The Efficacy of Doxazosin for Cocaine Users
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 35
- Registration Number
- NCT00880997
- Locations
- 🇺🇸
Baylor College of Medicine - Michael E. DeBakey VA Medical Center, Houston, Texas, United States
Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2010-08-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00730418
- Locations
- 🇰🇷
Samsung Medical Center, SEoul, Korea, Republic of
Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
- Conditions
- Kidney Stones
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 240
- Registration Number
- NCT00713739
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
Black Education and Treatment of Hypertension (BEAT HTN)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 99
- Registration Number
- NCT00661895
- Locations
- 🇺🇸
Creighton Community Health Center, Omaha, Nebraska, United States
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00648323
- Locations
- 🇨🇳
Pfizer Investigational Site, Taoyuan, Taiwan
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00646841
- Locations
Pfizer Investigational Site
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
- Conditions
- Prostatic HyperplasiaUrinary Retention
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 120
- Registration Number
- NCT00563485
- Locations
- 🇨🇳
Prince of Wales Hospital, Hong Kong, China
Nephropathy In Type 2 Diabetes and Cardio-renal Events
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 850
- Registration Number
- NCT00535925
- Locations
- 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
- Conditions
- Microvascular AnginaHypertension
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 10
- Registration Number
- NCT00424801
- Locations
- 🇩🇰
Aarhus Hospital, Aarhus, Denmark
Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
- Conditions
- Diabetes MellitusEssential HypertensionRenal Failure
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2007-05-10
- Lead Sponsor
- Yokohama City University Medical Center
- Target Recruit Count
- 98
- Registration Number
- NCT00295555
- Locations
- 🇯🇵
Yokohama City University Center Hospital, Yokohama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.